Sampling chest lymph nodes in patients with advanced lung cancer before radiation treatment
Endoscopic Nodal Staging in Oligometastatic Non-small Cell Lung Cancer (NSCLC) Being Treated With Stereotactic Ablative Radiotherapy (ENDO-SABR)
This study is testing if checking lymph nodes in the chest with special needles helps doctors better understand lung cancer in patients before they receive targeted radiation treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 29 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (London, Ontario and 1 other locations) |
| Trial ID | NCT04852588 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of sampling suspicious chest lymph nodes using endobronchial ultrasound-guided transbronchial fine needle aspiration (EBUS-TFNA) or transesophageal ultrasound-guided fine needle aspiration (EUS-FNA) in patients with oligometastatic non-small cell lung cancer (NSCLC) who are set to receive radical dose radiation. The research aims to determine if these sampling procedures provide valuable information about the extent of nodal disease compared to imaging alone. The treatment approach involves Stereotactic Ablative Radiotherapy (SABR), which delivers high-dose, precise radiation to small tumors. This study is crucial for understanding the role of lymph node assessment in the management of advanced lung cancer.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with oligometastatic non-small cell lung cancer and a good performance status.
Not a fit: Patients who have contraindications to endobronchial procedures or those with extensive metastatic disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment planning and outcomes for patients with advanced lung cancer by providing more accurate staging information.
How similar studies have performed: Other studies have shown promise in using similar lymph node sampling techniques in cancer management, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with oligometastatic non-small cell lung cancer (NSCLC), including a primary lung tumour (± hilar/mediastinal adenopathy) with up to 5 synchronous metastases * Radical treatment intent to all sites is recommended at multi-disciplinary tumour board or by discussion by medical oncologist and radiation oncologist and/or surgeon. * Age 18 years or older * Good performance status (Eastern Cooperative Oncology Group \[ECOG 0-1) with life-expectancy of at least 6 months as determined by enrolling physician * Patient has undergone staging investigations less than 3 months prior to registration. 1. Positron Emission Tomography (PET) / Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) brain (CT brain with contrast if contraindication to MRI) OR 2. CT chest/abdomen, radionucleotide bone scan and MRI of brain (CT brain with contrast if contraindication to MRI) * Pathologic confirmation of NSCLC Exclusion Criteria: * Contraindication to Endobronchial Ultrasound (EBUS) / Endoscopic Ultrasound (EUS) * Unable to provide consent for EBUS/EUS * Contraindication to chest radiotherapy * Pregnant or lactating women
Where this trial is running
London, Ontario and 1 other locations
- London Health Sciences Centre - London Regional Cancer Program — London, Ontario, Canada (Recruiting)
- Sunnybrook Health Sciences Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Inderdeep Dhaliwal, MD — London Health Sciences Centre, Lawson Health Research Institute
- Study coordinator: Inderdeep Dhaliwal, MD
- Email: Inderdeep.Dhaliwal@lhsc.on.ca
- Phone: 519-685-8500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.